SinoFresh(R) Nasal Spray Kills MRSA “Super-Bug” in Live Noses

SinoFresh® Passes First Key Test for Potential to Control “Super-Bug” MRSA

VENICE, FL–(EMWNews – August 18, 2008) – SinoFresh HealthCare, Inc. (OTCBB: SFSH)

announced preliminary results today from a successful in vivo pilot study

indicating that its patented SinoFresh® nasal spray was shown to be

useful in controlling the MRSA “super-bug” in the nasal passages. This

study utilized a recognized scientific model intended to demonstrate

SinoFresh® nasal spray’s ability to kill MRSA hiding in the nasal

passages. These favorable efficacy results follow an earlier, successful in

vitro study that was conducted at the Public Health Research Institute

under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis

Center and Hospital Infections Program.

The study showed that “SinoFresh® nasal spray used three times daily

appeared to effectively eliminate MRSA in the noses of the test animals

while leaving enough normal microbes to keep a normal population in the

nasal passages,” according to Dr. John Todhunter, consultant to SinoFresh,

who oversaw the study conducted at Virion Systems in Rockville, MD.

MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a

growing concern in the health care community. It incubates in the nasal

passages and then gets on the skin where it can cause severe, virulent

infections. The effect of MRSA can lead to disfigurement and sometimes

death. MRSA is also highly antibiotic resistant, making MRSA infections

difficult to treat. It is believed that approximately 2 – 3 million persons

in the U.S. walk around carrying MRSA in their nasal passages at any time

and elimination or severe reduction of nasal MRSA colonies is seen as a

potentially important weapon in fighting the spread of MSRA. The

antibiotic Mupirocin is currently used to reduce nasal MRSA loads.

SinoFresh® nasal spray attacks MRSA in the nasal passages by destroying

the “super-bug’s” cell walls and membranes by physical means rather than by

an antibiotic mechanism involving attack on the metabolism of the microbes

as occurs with the use of antibiotics. “Since bacteria can in effect change

their metabolism to be resistant to antibiotics, but can’t very well change

the laws of physics the chances for development of resistance to

SinoFresh® Nasal Spray’s mode of killing them is much lower,” said Dr.

Todhunter.

According to William Wilferth, VP for Research and Development at

SinoFresh, “These results have exceeded our expectations. The positive

results of this in vivo study gives us the solid scientific platform we

have needed in order to advance our efforts to fight MRSA to the next

level.”

Charles Fust, CEO of SinoFresh, noted that the data reported is extremely

encouraging and that there is a significant market need for new methods to

address MRSA control which is believed to be as many as 80 to 100 million

treatments annually in the United States alone.

About SinoFresh HealthCare, Inc.

SinoFresh HealthCare, Inc. (OTCBB: SFSH) is a developer and marketer of

innovative upper respiratory system therapies. The company is researching

broad-spectrum antiseptic approaches to reducing viral, bacterial and

fungal organisms that are suspected to cause pathogenesis of the mouth,

nose and throat. The company’s lead product, SinoFresh® Nasal and Sinus

Care, is a hygienic cleansing spray that kills germs and removes other

nasal-sinus irritants. The company is also researching how antiseptic

cleansing may alleviate chronic sinus distress, a condition that may affect

37 million Americans annually. SinoFresh® products are available in major

retail outlets nationwide. More information is available at

www.sinofresh.com.